NO20031521L - Assosiasjon av CB1-reseptorantagonist og et sibutramin, farmasöytiske preparater inneholdende denne samt dens anvendelse for behandling avfedme - Google Patents

Assosiasjon av CB1-reseptorantagonist og et sibutramin, farmasöytiske preparater inneholdende denne samt dens anvendelse for behandling avfedme

Info

Publication number
NO20031521L
NO20031521L NO20031521A NO20031521A NO20031521L NO 20031521 L NO20031521 L NO 20031521L NO 20031521 A NO20031521 A NO 20031521A NO 20031521 A NO20031521 A NO 20031521A NO 20031521 L NO20031521 L NO 20031521L
Authority
NO
Norway
Prior art keywords
association
sibutramine
obesity
treatment
receptor antagonist
Prior art date
Application number
NO20031521A
Other languages
English (en)
Other versions
NO20031521D0 (no
Inventor
Odile Piot-Grosjean
Philippe Picaut
Francois Petitet
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8854974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20031521(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20031521D0 publication Critical patent/NO20031521D0/no
Publication of NO20031521L publication Critical patent/NO20031521L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En assosiasjon av en CB1 -reseptorantagonist og sibutramin samt farmasøytiske preparater inneholdende assosiajonen, finner anvendelse for behandling av fedme.
NO20031521A 2000-10-04 2003-04-03 Assosiasjon av CB1-reseptorantagonist og et sibutramin, farmasöytiske preparater inneholdende denne samt dens anvendelse for behandling avfedme NO20031521L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0012646A FR2814678B1 (fr) 2000-10-04 2000-10-04 Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
PCT/FR2001/003022 WO2002028346A2 (fr) 2000-10-04 2001-10-01 Association d'un antagoniste du recepteur cb1 et de sibutramine, pour le traitement de l'obesite

Publications (2)

Publication Number Publication Date
NO20031521D0 NO20031521D0 (no) 2003-04-03
NO20031521L true NO20031521L (no) 2003-04-24

Family

ID=8854974

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031521A NO20031521L (no) 2000-10-04 2003-04-03 Assosiasjon av CB1-reseptorantagonist og et sibutramin, farmasöytiske preparater inneholdende denne samt dens anvendelse for behandling avfedme

Country Status (29)

Country Link
EP (1) EP1328269B2 (no)
JP (1) JP4221221B2 (no)
KR (1) KR20030036885A (no)
CN (1) CN100409845C (no)
AT (1) ATE267595T1 (no)
AU (2) AU9393601A (no)
BG (1) BG107739A (no)
BR (1) BR0114410A (no)
CA (1) CA2424934A1 (no)
DE (1) DE60103556T3 (no)
DK (1) DK1328269T5 (no)
EA (1) EA005924B1 (no)
EE (1) EE200300121A (no)
ES (1) ES2217191T5 (no)
FR (1) FR2814678B1 (no)
HR (1) HRP20030249A2 (no)
HU (1) HUP0302044A3 (no)
IL (1) IL155236A0 (no)
MX (1) MXPA03002845A (no)
NO (1) NO20031521L (no)
NZ (1) NZ524904A (no)
PL (1) PL362833A1 (no)
PT (1) PT1328269E (no)
SI (1) SI1328269T2 (no)
SK (1) SK4032003A3 (no)
TR (1) TR200401264T4 (no)
WO (1) WO2002028346A2 (no)
YU (1) YU26103A (no)
ZA (1) ZA200303015B (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2833842B1 (fr) * 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
AU2003217961B2 (en) 2002-03-08 2008-02-28 Signal Pharmaceuticals, Llc Combination therapy for treating, preventing or managing proliferative disorders and cancers
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
EP1490043A4 (en) 2002-03-26 2007-05-30 Merck & Co Inc SPIROCYCLIC AMIDS AS CANNABINOID RECEPTOR MODULATORS
WO2003082191A2 (en) 2002-03-28 2003-10-09 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
EP1499306A4 (en) 2002-04-12 2007-03-28 Merck & Co Inc BICYCLIC AMIDE
AU2003250117B2 (en) 2002-07-29 2007-05-10 F. Hoffmann-La Roche Ag Novel benzodioxoles
KR100674769B1 (ko) 2003-01-02 2007-02-28 에프. 호프만-라 로슈 아게 신규 씨비 1 수용체 역작용제
CN100395234C (zh) 2003-01-02 2008-06-18 霍夫曼-拉罗奇有限公司 新cb1受体反激动剂
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
AU2004252109B2 (en) 2003-06-11 2010-04-08 Merck Sharp & Dohme Corp. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
JP2007506654A (ja) 2003-06-20 2007-03-22 エフ．ホフマン−ラ　ロシュ　アーゲー Ｃｂ１受容体逆作動物質としての２−アミノベンゾチアゾール類
EP1498122A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid systems containing azetidine derivatives
EP1498123A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Emulsifying systems containing azetidine derivatives
EP1663215A1 (en) * 2003-09-02 2006-06-07 Solvay Pharmaceuticals GmbH Novel medical use of selective cb1- receptor antagonists
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
WO2005049615A1 (en) * 2003-11-21 2005-06-02 Pfizer Products Inc. Pyrazolo`1,5-a!`1,3,5! triazin -4-one derivatives as cb1 receptor antagonists
CA2547804A1 (en) 2003-12-08 2005-06-30 F. Hoffmann-La Roche Ag Novel thiazole derivatives
RU2360909C2 (ru) 2004-01-28 2009-07-10 Ф.Хоффманн-Ля Рош Аг Новые спиропентациклические соединения
JP2007536298A (ja) 2004-05-10 2007-12-13 エフ．ホフマン−ラ　ロシュ　アーゲー 肥満を処置するためのピロールまたはイミダゾールアミド
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
WO2006039334A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
FR2876689B1 (fr) 2004-10-14 2008-02-22 Aventis Pharma Sa Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide
AU2005298692A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions
AU2005298986A1 (en) 2004-10-27 2006-05-04 F. Hoffmann-La Roche Ag New indole or benzimidazole derivatives
RU2391337C2 (ru) 2004-11-09 2010-06-10 Ф.Хоффманн-Ля Рош Аг Производные дибензосуберона
PT1868999E (pt) 2005-04-06 2009-08-06 Hoffmann La Roche Derivados de piridino-3-carboxamida como agonistas inversos de cb1
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
AU2007222069A1 (en) * 2006-02-21 2007-09-13 Ampla Pharmaceuticals Inc. CB1 antagonists and inverse agonists
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
TW200815353A (en) 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
WO2008038143A2 (en) * 2006-06-22 2008-04-03 Medichem, S.A. Novel solid forms of rimonabant and synthetic processes for their preparation
WO2008026219A2 (en) * 2006-09-01 2008-03-06 Hetero Drugs Limited Novel polymorphs of rimonabant
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
CA2664310A1 (en) * 2006-09-25 2008-04-03 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
EP1953144A1 (en) * 2007-01-30 2008-08-06 Sandoz AG Novel polymorphic forms of N-piperidino-5-(4-chlorophenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolecarboxamide
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
CA2709863A1 (fr) * 2007-12-18 2009-09-03 Sanofi-Aventis Derives d'azetidines, leur preparation et leur application en therapeutique
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
BRPI0902481B8 (pt) 2009-07-31 2021-05-25 Soc Beneficente De Senhoras Hospital Sirio Libanes composição farmacêutica compreendendo hemopressina e seu uso.
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61928B1 (en) † 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
JPH04360167A (ja) * 1991-06-06 1992-12-14 Mitsubishi Kasei Corp 近接帯電装置
FR2713225B1 (fr) † 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
JPH07209959A (ja) * 1994-01-24 1995-08-11 Ricoh Co Ltd 帯電装置
US5596106A (en) † 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
CA2269660A1 (en) * 1996-10-31 1998-05-07 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
US6153524A (en) * 1997-07-29 2000-11-28 Silicon Genesis Corporation Cluster tool method using plasma immersion ion implantation
EP0920864A1 (en) † 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
IL141769A0 (en) † 1998-09-11 2002-03-10 Aventis Pharma Sa Azetidine derivatives, preparation and medicines containing them
FR2783246B1 (fr) * 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation

Also Published As

Publication number Publication date
YU26103A (sh) 2006-08-17
CN100409845C (zh) 2008-08-13
EA005924B1 (ru) 2005-08-25
ZA200303015B (en) 2004-02-26
AU2001293936B2 (en) 2007-01-25
SK4032003A3 (en) 2003-09-11
WO2002028346A3 (fr) 2002-08-29
BG107739A (bg) 2004-01-30
DK1328269T3 (da) 2004-09-20
EE200300121A (et) 2005-04-15
EP1328269B2 (fr) 2008-07-30
IL155236A0 (en) 2003-11-23
EP1328269A2 (fr) 2003-07-23
HUP0302044A3 (en) 2005-05-30
SI1328269T2 (sl) 2008-12-31
NO20031521D0 (no) 2003-04-03
SI1328269T1 (en) 2004-10-31
CN1473040A (zh) 2004-02-04
FR2814678B1 (fr) 2002-12-20
NZ524904A (en) 2004-11-26
DE60103556D1 (de) 2004-07-01
BR0114410A (pt) 2004-02-17
DE60103556T3 (de) 2009-04-09
AU9393601A (en) 2002-04-15
DK1328269T5 (da) 2009-03-16
MXPA03002845A (es) 2004-09-10
KR20030036885A (ko) 2003-05-09
WO2002028346A2 (fr) 2002-04-11
PL362833A1 (en) 2004-11-02
CA2424934A1 (fr) 2002-04-11
ATE267595T1 (de) 2004-06-15
JP2004512279A (ja) 2004-04-22
ES2217191T5 (es) 2009-02-16
HRP20030249A2 (en) 2005-02-28
DE60103556T2 (de) 2005-06-30
EP1328269B1 (fr) 2004-05-26
TR200401264T4 (tr) 2004-07-21
HUP0302044A2 (hu) 2003-11-28
JP4221221B2 (ja) 2009-02-12
DK1328269T4 (da) 2008-11-24
EA200300441A1 (ru) 2003-08-28
PT1328269E (pt) 2004-08-31
ES2217191T3 (es) 2004-11-01
FR2814678A1 (fr) 2002-04-05

Similar Documents

Publication Publication Date Title
NO20031521L (no) Assosiasjon av CB1-reseptorantagonist og et sibutramin, farmasöytiske preparater inneholdende denne samt dens anvendelse for behandling avfedme
IL139080A0 (en) Btx inhibitors and methods for their indentification and use
NO2014009I2 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser
DE60007095D1 (de) Calanolide zur hemmung von btk
HUP0400908A3 (en) Pyrazole compounds useful as protein kinase inhibitors, their use and pharmaceutical compositions containing them
CA2366932A1 (en) Cyclic protein tyrosine kinase inhibitors
NO20060030L (no) Kombinasjonsterapi for b-cellelidelser
NO333265B3 (no) Substituerte dihydrokinazoliner, fremgangsmåte for fremstilling derav, anvendelse av en slik forbindelse samt medikament inneholdende denne.
EP1577317A4 (en) NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, MEDICINAL COMPOSITIONS COMPRISING SAID DERIVATIVES AND MEDICAL USE OF SAID DERIVATIVES
DE69917230D1 (de) Kombinationspräparat, das selektive nmda nr2b-antagonisten und cox-2 inhibitoren enthält
MY137620A (en) Therapeutic treatment
NO20035602D0 (no) Sammensetning som omfatter en PDE-4-inhibitor og H1- reseptorantagonist, samt anvendelse derav til fremstilling av et medikament forbehandling av åndedrettsykdommer
AP2004003190A0 (en) Broaspectrum substituted benzisoxazole sulfonamideHIV protease inhibitors.
WO2001004354A3 (en) Use of ras inhibitors of inhibiting muscle atrophy
DK1176148T3 (da) Benzothiadiazinforbindelser, fremgangsmåde til fremstilling heraf samt farmaceutiske sammensætninger indeholdende disse
DE60324816D1 (de) Impfstoffe gegen allergien
MXPA04005226A (es) 1,3-diarilprop-2-en-1-onas, composiciones que las contienen y su utilizacion.
MXPA04001878A (es) Composiciones medicinales que comprenden antagonista del receptor de angiotensina ii.
AU2003275127A8 (en) P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
NO20040471L (no) 5,6,6a,1 1b-tetrahydro-7-oksa-5-azabenzo[c]fluoren-6-karboksylsyrederivater som NMDA-antagonister
GB0228706D0 (en) Novel therapeutic target
NL1022139A1 (nl) Product: Precisiedeuvel (voor precisiemachines en instrumenten).
GB0228699D0 (en) Novel therapeutic target
PL1668027T3 (pl) Cykliczne peptydy działające jako antagoniści Urotensyny-II
ZA200407798B (en) Protein isolates, compositions comprising protein isolates and methods of use.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application